COCM
TEVA icon

Charter Oak Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Charter Oak Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-503
Closed -$5K – 802
2022
Q2 		$5K Hold
503
– – ﹤0.01% 711
2022
Q1 		$5K Hold
503
– – ﹤0.01% 765
2021
Q4 		$5K Hold
503
– – ﹤0.01% 704
2021
Q3 		$5K Hold
503
– – ﹤0.01% 681
2021
Q2 		$5K Hold
503
– – ﹤0.01% 674
2021
Q1 		$6K Hold
503
– – ﹤0.01% 616
2020
Q4 		$5K Buy
+503
New +$4.82K ﹤0.01% 610

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Charter Oak Capital Management's TEVA Position: Q3 2022 in Review

Charter Oak Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2022, closing a stake of 503 shares — an estimated $5K sold.

Charter Oak Capital Management first reported a position in TEVA in Q4 2020 and held it in 7 quarters. The position peaked at $6K in Q1 2021. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

  • Charter Oak Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Charter Oak Capital Management sold 503 Teva Pharmaceuticals shares in Q3 2022, an estimated $5K.
  • Charter Oak Capital Management first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 7 quarters.
  • Charter Oak Capital Management's Teva Pharmaceuticals position peaked at $6K in Q1 2021.
  • 430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.